Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.41 CAD 0.71% Market Closed
Market Cap: 140.3m CAD

Cardiol Therapeutics Inc
Effect of Foreign Exchange Rates

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cardiol Therapeutics Inc
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Effect of Foreign Exchange Rates
CA$1.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Effect of Foreign Exchange Rates
$19m
CAGR 3-Years
N/A
CAGR 5-Years
19%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Effect of Foreign Exchange Rates
CA$9.4m
CAGR 3-Years
-35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Effect of Foreign Exchange Rates
-$2.4m
CAGR 3-Years
55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Effect of Foreign Exchange Rates
CA$242k
CAGR 3-Years
-69%
CAGR 5-Years
-33%
CAGR 10-Years
-28%
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
140.3m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
2.82 CAD
Undervaluation 50%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
1.3m CAD

Based on the financial report for Sep 30, 2025, Cardiol Therapeutics Inc's Effect of Foreign Exchange Rates amounts to 1.3m CAD.

What is Cardiol Therapeutics Inc's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 1Y
12%

Over the last year, the Effect of Foreign Exchange Rates growth was 12%.

Back to Top